Factors that cause high blood pressure condition in pregnant women protect against breast cancer

April 26, 2010, Federation of American Societies for Experimental Biology

Preeclampsia is a high blood pressure syndrome in pregnant mothers that is caused when the blood supply in the placenta of the developing baby is restricted. The blood-deprived placenta releases factors that cause the raise in blood pressure in the mother. Doctors have to monitor these women closely and they may be forced to deliver the baby early to protect the mother and the baby. Most women's blood pressure returns to normal levels after they deliver the placenta.

A Risk With Benefits

Women that develop preeclampsia paradoxically seem to have reduced incidence of developing breast cancer. But why this serious condition may have other beneficial effects is unknown.

Anne Gingery of the Department of Physiology and Pharmacology at the University of Minnesota Medical School, Duluth, MN, has investigated how specific factors released from the placenta of women with preeclampsia inhibit the growth of breast cancer cells. Gingery will be presenting her latest findings at the 2010 Experimental Biology meeting in Anaheim, CA from April 24-28. Her presentation is entitled "Soluble Endoglin Inhibits Breast Cancer ."

Dr. Gingery's research uses a rat model with preeclampsia, which they induce by restricting the blood flow to the rat's placenta with clips. The has many blood vessels, so the factors released during preeclampsia end up in the blood stream. The serum - what is left after the cells are filtered out of the blood - of these animals possesses anti-cancer properties. Gingery tested an array of breast cancer cells treated with the serum that resulted in decreased growth of cancer cells.

The Factors Involved

Gingery studies two factors released during preeclampsia: sFlt-1 and soluble endoglin. sFlt-1 is a soluble version of a protein called VEGF (vascular endothelial growth factor), which regulates the growth of cells. The other factor, soluble endoglin, is a co-receptor for TGF-{beta} (transforming growth factor beta). The TGF-{beta} pathway controls growth and Gingery proposes that soluble endoglin inhibits cell growth by reducing the signaling of this pathway. The TGF-{beta} signaling pathway is an important factor in breast cancer development and progression. According to Gingery, at the early stages of cancer this pathway often suppresses tumor growth, but in advanced cancer it can actually promote cancer progression.

Things Are Complicated: The Factors Only Protect the Mothers

Gingery's work expanded to look at the pups born from mother rats with preeclampsia. Surprisingly, the preliminary results reveal that the pups born from the mother's with preeclampsia are more likely to develop breast tumors. The group is examining the time it takes to develop tumors and the characteristics of the tumors. On-going research is evaluating whether the mothers with the preeclampsia will have a reduced incidence of breast tumors.

Gingery speculates that perhaps the factors released during preeclampsia affect the stem cells of the mammary gland in some way that changes how the cells develop, which may affect protection against cancer. But she reiterates that this research is in its early stages and much is still unknown.

By studying the affects of preeclampsia on the protection against , Gingery hopes to identify new targets that can be used in prevention and the development of therapeutics. "Preeclampsia is not a condition we want any mother to endure," explains Gingery. "We are simply using a unique way to find factors to be used for care and treatment of cancer. Sometimes it just takes looking at a question differently."

Related Stories

Recommended for you

Stem cell vaccine immunizes lab mice against multiple cancers

February 15, 2018
Stanford University researchers report that injecting mice with inactivated induced pluripotent stem cells (iPSCs) launched a strong immune response against breast, lung, and skin cancers. The vaccine also prevented relapses ...

Induced pluripotent stem cells could serve as cancer vaccine, researchers say

February 15, 2018
Induced pluripotent stem cells, or iPS cells, are a keystone of regenerative medicine. Outside the body, they can be coaxed to become many different types of cells and tissues that can help repair damage due to trauma or ...

Team paves the way to the use of immunotherapy to treat aggressive colon tumors

February 15, 2018
In a short space of time, immunotherapy against cancer cells has become a powerful approach to treat cancers such as melanoma and lung cancer. However, to date, most colon tumours appeared to be unresponsive to this kind ...

Can our genes help predict how women respond to ovarian cancer treatment?

February 15, 2018
Research has identified gene variants that play a significant role in how women with ovarian cancer process chemotherapy.

First comparison of common breast cancer tests finds varied accuracy of predictions

February 15, 2018
Commercially-available prognostic breast cancer tests show significant variation in their abilities to predict disease recurrence, according to a study led by Queen Mary University of London of nearly 800 postmenopausal women.

Catching up to brain cancer: Researchers develop accurate model of how aggressive cancer cells move and spread

February 15, 2018
A brief chat at a Faculty Senate meeting put two University of Delaware researchers onto an idea that could be of great value to cancer researchers.


Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.